Holen Sie sich die Stockscreener-App
1.95
14.10%
-0.32
Schlusskurs vom Vortag:
$2.27
Offen:
$2.26
24-Stunden-Volumen:
69,590
Relative Volume:
1.97
Marktkapitalisierung:
$22.57M
Einnahmen:
$3.35M
Nettoeinkommen (Verlust:
$86,000
KGV:
126.62
EPS:
0.0154
Netto-Cashflow:
$2.67M
1W Leistung:
+7.14%
1M Leistung:
-3.47%
6M Leistung:
+16.77%
1J Leistung:
+80.56%
1-Tages-Spanne:
$1.89
$2.30
1-Wochen-Bereich:
$1.85
$2.42
52-Wochen-Spanne:
$0.9811
$2.95
Therapeuticsmd Inc Stock (TXMD) Company Profile
Firmenname
Therapeuticsmd Inc
Sektor
Telefon
561-961-1900
Adresse
951 YAMATO ROAD, SUITE 220, BOCA RATON, FL
Compare TXMD vs TAK, HLN, TEVA, ZTS, UTHR
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
TXMD
Therapeuticsmd Inc
|
1.95 | 22.57M | 3.35M | 86,000 | 2.67M | 0.0154 |
TAK
Takeda Pharmaceutical Co Adr
|
15.63 | 49.39B | 29.91B | 1.30B | 3.49B | 0.4056 |
HLN
Haleon Plc Adr
|
8.96 | 39.55B | 14.54B | 2.22B | 2.58B | 0.4871 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
31.48 | 36.66B | 17.53B | 1.58B | 444.18M | 1.3457 |
ZTS
Zoetis Inc
|
78.71 | 33.00B | 9.51B | 2.64B | 2.14B | 6.0361 |
UTHR
United Therapeutics Corp
|
536.59 | 22.78B | 3.17B | 1.29B | 1.01B | 27.09 |
Therapeuticsmd Inc Stock (TXMD) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2020-08-07 | Herabstufung | Jefferies | Hold → Underperform |
| 2020-05-19 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2019-12-02 | Eingeleitet | Guggenheim | Buy |
| 2019-10-17 | Eingeleitet | H.C. Wainwright | Buy |
| 2019-04-30 | Fortgesetzt | Noble Capital Markets | Outperform |
| 2018-06-15 | Eingeleitet | JP Morgan | Overweight |
| 2017-09-08 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2017-07-11 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2017-05-09 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2016-11-22 | Fortgesetzt | Jefferies | Buy |
| 2016-11-22 | Eingeleitet | Oppenheimer | Outperform |
| 2016-11-07 | Fortgesetzt | Guggenheim | Buy |
| 2016-04-04 | Eingeleitet | Goldman | Buy |
| 2015-12-08 | Bestätigt | Jefferies | Buy |
| 2015-12-08 | Bestätigt | Stifel | Buy |
| 2015-09-21 | Bestätigt | Jefferies | Buy |
| 2015-06-09 | Eingeleitet | Guggenheim | Buy |
| 2014-07-08 | Eingeleitet | FBR Capital | Outperform |
| 2014-04-17 | Bestätigt | Noble Financial | Buy |
| 2014-01-28 | Bestätigt | Noble Financial | Buy |
Alle ansehen
Therapeuticsmd Inc Aktie (TXMD) Neueste Nachrichten
TherapeuticsMD Inc (TXMD) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
TherapeuticsMD Inc (TXMD) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
TherapeuticsMD Inc (TXMD) Valuation: PE, PB & Fair Value Analysis - TradingKey
TherapeuticsMD Inc (TXMD) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
TherapeuticsMD Inc (TXMD) Institutional Confidence - TradingKey
TherapeuticsMD Inc (TXMD) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
TherapeuticsMD Inc. stock underperforms Thursday when compared to competitors - MarketWatch
TherapeuticsMD Inc (TXMD) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
TherapeuticsMD Inc (TXMD) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
TherapeuticsMD Inc (TXMD) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
TXMD Q3 2023 Earnings: EPS Misses Estimates Amid Continued Cash BurnNet Income Trends - newsline.com
TherapeuticsMD (TXMD) Gains 3.64%, Tests Resistance at $2.39High Low Breadth - newsline.com
TherapeuticsMD Inc. stock outperforms competitors on strong trading day - MarketWatch
TXMD Q3 2023 Earnings: EPS Misses Estimates Sharply, Yet Stock Surges 20.9%EPS Surprise History - newsline.com
TXMD Q3 2023 Earnings: Wider-than-Expected Loss Highlights Operational ChallengesProfit Inflection Point - newsline.com
TherapeuticsMD Inc. stock underperforms Wednesday when compared to competitors - MarketWatch
TherapeuticsMD (TXMD) Nears Support Amid Modest Selling PressureIndex Put Call - newsline.com
TherapeuticsMD Inc. (TXMD) Gains Ground as Shares Push Toward Resistance ZoneAAII Neutral - newsline.com
TherapeuticsMD Inc. stock underperforms Monday when compared to competitors - MarketWatch
TherapeuticsMD Inc. stock underperforms Thursday when compared to competitors despite daily gains - MarketWatch
TherapeuticsMD Inc. stock underperforms Tuesday when compared to competitors - MarketWatch
TXMD Q3 2023 Earnings: Deep EPS Miss Overshadowed by Strategic ProgressNegative Surprise Momentum - newsline.com
TXMD Q3 2023 Earnings: Significant EPS Miss Amid Operational ChallengesTrough Earnings Signal - The Legal Advocate
TXMD Q3 2023 Earnings: EPS Misses Estimates, Stock DeclinesPost-Earnings Drift - newsline.com
TXMD Q3 2023 Earnings: EPS Misses Estimates by Wide Margin Amidst Operational Challenges - newsline.com
TXMD Q3 2023 Earnings: A Significant EPS Miss Amid No Reported RevenueLow Growth Earnings - newsline.com
TherapeuticsMD (TXMD) Edges Higher as Support Holds Near $2.01Post-Earnings Moves - Newser
What TherapeuticsMD TXMD flagged as biggest challenges ahead Q3 2023 EPS Misses ViewsBanking Earnings Report - The Legal Advocate
TherapeuticsMD Announces First Quarter 2026 Financial Results - BioSpace
TXMD Reports Strong Q1 Revenue Growth and Explores Strategic Alt - GuruFocus
Is TherapeuticsMD (TXMD) 13.4% Overvalued After Q1 2026 Earnings - GuruFocus
[10-Q] TherapeuticsMD, Inc. Quarterly Earnings Report - Stock Titan
TherapeuticsMD Reports Quarterly Profit, Evaluates Strategic Alternatives - TipRanks
TherapeuticsMD: Q1 Earnings Snapshot - marketscreener.com
TherapeuticsMD swings to Q1 net income as license revenue rises - TradingView
TherapeuticsMD (TXMD) details Q1 2026 results and strategic review - Stock Titan
TherapeuticsMD | 8-K: TherapeuticsMD Announces First Quarter 2026 Financial Results - Moomoo
What TherapeuticsMD (TXMD) flagged as biggest challenges ahead | Q3 2023: EPS Misses ViewsStock Trading Network - Newser
TherapeuticsMD Inc. stock underperforms Friday when compared to competitors - MarketWatch
TXMD Stock Price, Quote & Chart | THERAPEUTICSMD INC (NASDAQ:TXMD) - ChartMill
Finanzdaten der Therapeuticsmd Inc-Aktie (TXMD)
Umsatz
Nettogewinn
Free Cashflow
ENV
11.23%
0.45%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):